Barrons : Airbus Is a Steady Stock for Turbulent Times. Why It Could Soar 35%.

Airbus Is a Steady Stock for Turbulent Times. Why It Could Soar 35%.

Airbus is ready for takeoff. Investors in the European aerospace company could see gains of more than 35% over the next 12 months as the company boosts production amid surging demand, analysts say.

“Airbus is on a very strong growth trajectory regardless of a recession and postpandemic normalization,” says Colin Scarola, an analyst at financial research company CFRA. He sees the stock (ticker: AIR.France) rising to 140 euros ($143) over the next year, up 35% from its recent level of €104. Plus, the stock yields a 1.4% dividend currently. U.S.-based investors could consider buying the American depositary receipts (EADSY.)

The company on July 27 reported better-than-expected first-half profits. Despite the improving profitability, the stock has followed the broader market down. The shares have lost about 8% this year, roughly in line with the performance of the Paris CAC 40 index, which tracks leading French-listed companies.

Still, the pullback has made the shares cheap relative to projected income. They were recently trading at 21 times forward earnings, according to data from Morningstar . That is lower than the five-year average of 24.

During the earnings announcement, Airbus slashed its target 2022 production to 700 commercial aircraft from 720 previously. “In the short term, the current supply-chain challenges lead us to adjust the ramp-up steps in 2022 and ’23,” said CEO Guillaume Faury on the earnings call. The company now expects to produce 65 planes a month in early 2024, later than originally expected.

However, Airbus is maintaining its long-term target of producing 75 of its A320 model aircraft a month by 2025, up from 60 monthly before the pandemic. “Going up to 75 might sound aggressive, but it’s in line with production increases we’ve seen from Airbus before the pandemic,” Scarola says. Plus, China’s three biggest state-owned airlines recently agreed to buy 300 planes from Airbus.

Scarola doesn’t see aircraft demand slipping despite the increasing likelihood of a global economic slowdown. “We are currently at a depressed level of aircraft deliveries relative to global GDP,” he says. “Even if we go through something worse than the financial crisis, I think Airbus deliveries have to climb about 40%.”

“The biggest risk to their positioning today is the cost issues,” says Allegra Dawes, an analyst at financial research firm Third Bridge. All manufacturers, especially those in Europe, are suffering from the considerable jumps in commodity prices, especially the surge in energy prices since Russia’s invasion of Ukraine.

Despite a recent pullback in prices, energy-heavy aluminum was about 36% more expensive recently than it was before the pandemic. That is a key concern, given that aircraft fuselages are largely made with aluminum. “To a certain extent, Airbus will be able to mitigate a lot of the cost issues with price increases,” Dawes says.

There are real and potential supply threats for any manufacturer securing titanium, a metal used in aircraft construction, especially for engine components. Russia, which has restricted exports of some key commodities, is the third-largest producer of the metal.

“We see a shift away from Russia for sourcing, but some processing of specific parts will take a little longer,” Dawes says.

Meanwhile, China is the largest titanium producer, controlling more than half of the world’s supply. Unfortunately, relations between the communist country and the West are deteriorating fast. Depending on how tense things get with China, the supply problems could get even worse.

Still, on balance, the potential upside for Airbus outweighs the possible risks.

Barrons : M&A Is Sputtering. Blame Inflation, Rates, and Volatility.

M&A Is Sputtering. Blame Inflation, Rates, and Volatility.

It has been a big year for newsmaking M&A, but that hasn’t translated into a big wave of deal activity.

July volumes for mergers and acquisitions are down 57% on a dollar basis, while the deal count is off 53% year over year, according to Goldman Sachs data.

This sharp drop in activity comes despite recent headline-making deals such as JetBlue Airway JBLU 0.00% ’s (ticker: JBLU) acquisition of Spirit Airlines SAVE –0.16% (SAVE) and Amazon.com AMZN –1.24% ’s (AMZN) plans to buy 1Life Healthcare (ONEM), parent of One Medical, not to mention the litigious saga over Elon Musk’s Twitter TWTR +3.56% (TWTR) bid.

Bank executives lamented the M&A slowdown in earnings calls last month, and merger bankers are bracing for bonuses shrinking by as much as 25%, says compensation consultant Johnson Associates.

Reasons for the M&A drop are manifold. While there may be logical reasons for companies to merge, market volatility makes it difficult to agree on price. The Cboe Volatility IndexVIX –1.35% , or VIX, stood at 24 in July, up from 17 a year ago. Deals have also grown more expensive to finance. High-yield bond yields hit 7.98%—double from a year ago. Investment-grade bond yields have more than doubled from last year and now stand at 4.6%, according to Goldman data.

While Goldman is bearish on deal making in the short term, expecting an 18% drop in activity over the next year, the bank is optimistic about a turnaround. “As those strains on lending ease and as volatility subsides over time, likely many of these delayed transactions proceed to announcement and closing,” wrote Richard Ramsden, its head of financial research.

Barrons : GE Stock Is a Buy as Breakup Looms

GE Stock Is a Buy as Breakup Looms

So, it comes to this— General Electric GE +0.94% , once arguably the greatest of American companies, will cease to exist, at least as the industrial titan it once was.

After more than 20 years of decline, the company is entering the final stages of a process that has seen the General Electric of old slowly dismantled—the corporate powerhouse founded by Thomas Edison doesn’t even make lightbulbs anymore—until just three parts remain. Soon, those units—GE’s aviation, energy, and healthcare businesses—will be separated into individual companies, starting with GE Healthcare, which could be spun off in early 2023. It’s a sad end for a giant humbled by missteps.

Every ending, however, is also a new beginning. Unencumbered by the past—and past mistakes—the three companies have the potential to compete more fiercely than the old cumbersome behemoth could. What’s more, they should earn higher stock market valuations separately than they could as part of an unwieldy conglomerate.


Illustration by Eddie Guy
For investors, it’s time to stop thinking about what GE was and instead look ahead to what it will be. Once they exchange their GE shares for shares of the three separate companies, investors could start seeing some nice gains.

“People aren’t focused enough on the new GE,” says BofA Securities analyst Andrew Obin, who has a Buy rating on the shares (ticker: GE). “Investors are fighting the last war.”

It’s hard to blame them. Back in the 1980s and 1990s, GE stock returned more than 25% a year, on average. And $100 invested in the company at the start of the ’80s turned into more than $9,000 over that two-decade span, more than triple $2,700 invested in the S&P 500SPX –0.16% index. Performance like that gave management carte blanche to do whatever it wanted, and made CEO Jack Welch a star.

But by 2000, cracks were appearing. GE’s debt had ballooned, its businesses were less efficient, and Welch picked the perfect time to leave. He was succeeded by Jeffrey Immelt, whose deal making grew GE Healthcare and led to some perilous developments: the expansion of GE Capital, which was battered by bad bets during the 2008-09 financial crisis, and the disastrous acquisition of the energy businesses of France’s Alstom.

By the end of 2018, GE’s market cap had tumbled to less than $70 billion from roughly $500 billion at the start of the Immelt era, and the company had long ago ceded its place as the largest industrial stock. GE’s decline was particularly painful for shareholders, who lost 7% a year from 2000 to 2018, even as the S&P 500 returned 5% annually, on average, over the same span.

With confidence in General Electric shattered, investors have been unwilling to give management much credit for a turnaround plan, even though current CEO Larry Culp, who replaced Immelt’s ousted successor, John Flannery, in 2018, has a solid one.

Culp set about shrinking GE Capital, infused life back into the company’s management culture, and pared the corporation to a more manageable size. Among his accomplishments: the sale of GE’s biopharma division to Danaher DHR +0.36% (DHR) for $21 billion, with proceeds used to pay down debt; the end of GE Capital as a separate entity, though about $36 billion in legacy assets remain on the books; and even opening up the conglomerate’s famously opaque accounting.

The turnaround might have gone smoothly, too, if it hadn’t been for Covid-19. The pandemic dramatically reduced the number of people on planes, hurting GE’s aviation business, and kept people out of the doctor’s office, except for only the most necessary procedures, a problem for GE Healthcare. Culp continued to cut costs and pay down debt, but the coronavirus continues to create headaches for him and the company. Ultimately, he and the board concluded that they had three great businesses that could be managed more effectively on their own.

It was time to break up General Electric.

On Nov. 9, 2021, GE announced a plan to split itself into aerospace, healthcare, and power-generation concerns. The market initially cheered, sending the stock up to more than $116 a share that day. But November was also the month in which the Federal Reserve started to really worry about inflation and make clear that interest rates could rise. That hurt the entire market, but GE even more—since the end of November, its stock is down about 22% while the S&P 500 is off 9% and S&P industrial stocks are, on average, down 5%.

But at $73 a share, General Electric appears to be trading for far less than the combined value of its three remaining pieces.

Take GE’s aerospace unit, which makes engines for both Boeing BA –0.88% ’s 737 MAX and the Airbus A321neo. In the decade before the pandemic, its sales climbed at a 6% average annual rate, generating $58 billion in cumulative earnings before interest, taxes, depreciation, and amortization, or Ebitda, with an average operating profit margin of almost 21%. Covid hurt—at $21.3 billion in 2021, sales were 35% below 2019’s—but the division still generated $4 billion in Ebitda, on operating profit margins of nearly 14%.

A recovery is in the cards, however, especially with travel bouncing back. In fact, results at aerospace companies in general are expected to return to pre-Covid-levels by 2024. In the past, large aerospace supplier stocks, including Raytheon Technologies RTX +0.27% (RTX) and Safran (SAF.France), typically traded with an enterprise value to Ebitda ratio in line with the S&P 500’s, or about 11 times 2024 estimates. If GE Aerospace, which is expected to generate Ebitda of $7.7 billion in 2024, were to command that valuation, it would be worth nearly $85 billion. That’s still well below where it was just a few years ago, observes Neuberger Berman portfolio manager Evelyn Chow. ”We used to talk about aviation at a $100 billion valuation,” she says.

And the spinoff might not be the end of the saga for GE Aerospace, which is expected to be led by Culp. The aerospace and defense industries have a long history of mergers—Raytheon’s combination with United Technologies ’ aerospace unit in 2020 is the most recent example—and an eventual merger with Lockheed Martin (LMT) or Honeywell Internationa l (HON) could make a lot of sense—and lead to an even higher valuation. “The dream combination was always GE Aviation and Honeywell aerospace,” says T. Rowe Price portfolio manager Jason Adams. “Together, that would be [the] pre-eminent company in global aerospace.”

GE’s healthcare business, which makes diagnostic imaging equipment including MRIs and CT and ultrasound scanners, also looks set to thrive as an independent company—even if it hasn’t been hitting on all cylinders recently.

Like aerospace, healthcare was hurt by the pandemic, as patients avoided going to the doctor for anything but the most serious illnesses. This year was supposed to be better, but GE Healthcare’s profit margin fell to 12.3% in the first quarter from 16.2% a year earlier and about 19% before the pandemic.

Margins bounced back in the second quarter, however, and if that continues, they should get back to pre-Covid levels approaching 18% to 20% over the coming quarters. One reason: An independent GE Healthcare would be able to make small acquisitions to complement organic growth. “We may be discussing 50, 60 different companies routinely,” says Peter Arduini, CEO of GE’s healthcare unit, who says that it aims to be more agile when it’s on its own.

Some bulls see similarities between the GE business and Danaher, where Culp was CEO from 2001 through 2014. GE Healthcare, however, is no Danaher. Its sales are growing by 3% to Danaher’s 6%, and it has less recurring revenue, about 50% for GE versus 75% for Danaher.

A more pessimistic comparison would have it trading near nine times Ebitda, like Philips (PHG), which makes imaging and diagnostic equipment similar to GE’s. Still, the GE unit’s margins of 18% are nearly double Philips’ about 9%.

The most realistic comparison might be to Siemens Healthineers (SHL.Germany). The oddly named company was boosting sales at 3% a year, on average, before the pandemic, about in line with GE Healthcare, while its profit margin was about 16%, just a touch lower than the GE business’. If the companies fetched similar valuations, GE Healthcare would be worth $50 billion to $60 billion. Siemens Healthineers is larger; it’s valued at $70 billion.

If the future is relatively clear for GE Aerospace and GE Healthcare, it is less so for GE’s power business. Its renewable-energy business, focused on building wind turbines, is losing money, while investors worry that its natural-gas equipment business will eventually disappear as governments curb the use of fossil fuels. About the only thing that’s certain is the new company’s name: GE Vernova. The latter word denotes green and new.

The wind business, in particular, is problematic, and not just for GE. Over the past 12 months, the dominant wind turbine makers—GE, Siemens Gamesa Renewable Energy (SGRE.Spain), and Vestas Wind Systems (VWS.Denmark)—have lost a combined $2.4 billion, despite good demand for renewable energy.

The problem, says Culp, is that “it’s an immature industry.” Wind technology is changing rapidly, with new-generation turbines arriving before the older ones achieve high enough production volume to truly drive costs down. Wind farms also take years to build—usually on fixed contracts—so inflation like today’s can turn them into money losers. And erratic government investment-tax policies lead to boom-bust cycles.

To truly cash in on demand for alternative energy, the industry must better manage costs, slow the pace of new-product introductions, and negotiate contracts that pass through higher raw material costs. Until that happens, the business will earn roughly the same valuation as Siemens Gamesa and Vestas. They fetch about 1.25 times sales, making GE Renewables worth about $18 billion.

GE Power also makes huge—and hugely complex—natural-gas turbines for power companies. Investors haven’t given that business much credit, either, as they look ahead to the twilight of fossil fuels. Russia’s invasion of Ukraine is likely to stretch that process out, and even the end of natural gas won’t make the business evaporate completely because the turbines can be modified to burn a mixture of hydrogen gas and natural gas, or even pure hydrogen.

“I certainly perceive less of this ‘melting ice cube’ on gas,” says Neuberger’s Chow, who runs a decarbonization strategy at the investment firm. “Especially after all the geopolitical conflict, transitional fuel is incredibly important.”

Comparisons to Siemens Energy (ENR.Germany), which trades at about two times Ebitda, or Mitsubishi Heavy Industries (7011.Japan), which trades at seven times, seem to make sense. A multiple between the two—say five times—appears appropriate, given that GE Power has been producing the group’s best operating profits over the past year. At that valuation, Power could be worth up to $10 billion. The new company, which would also include GE’s digital and grid-technology businesses, could be worth $28 billion, or a little less than one times annual sales.

GE Vernova CEO Scott Strazik is certainly optimistic. “We’re much more focused on taking the portfolio of businesses we have and strategically positioning [them] to lead in the energy transition,” he says.

Add it all up and the three businesses could be worth roughly $160 billion—about double what an intact General Electric trades for now.

In figuring the likely combined value of a broken-up GE, its balance sheet must be taken into account. It’s still somewhat ugly, but not as much as it used to be. GE’s pension obligations, though huge at $95 billion, are 88% funded, based on generally accepted accounting principles. This means that GE won’t have to make cash contributions to meet regulatory funding requirements, says accounting expert Robert Willens, who adds that GAAP standards tend to inflate the value of obligations.

Scarier are GE’s liabilities for long-term-care insurance policies—which it stopped selling a decade and a half ago. General Electric took a $9.5 billion hit in 2017 because the premiums weren’t covering the claims. It has now set aside $14.5 billion to cover future payouts. Still, it must put more aside. Alternatively, it could pay another company to take the liabilities off its books entirely. Either way, resolving the issue will be costly, but less so than it once would have been.

All told, GE’s debt sits around $32 billion. Total cash, along with stock in oilfield services and equipment company Baker Hughes (BKR) and aircraft sales and leasing concern AerCap Holdings (AER), comes to almost $20 billion. That puts net debt at about $12 billion—less than two times the about $6.9 billion in Ebitda that GE earned over the past 12 months. The average industrial company’s figure is 2.2 times. Overall, says Obin, “they did fix the balance sheet.”

If all of GE’s net debt and other liabilities are toted up, along with its assets and some money for duplicating corporate overhead, the market capitalization of the three units to be created should be $130 billion to $140 billion, or roughly $125 a share. That would be more than 70% above the $73 at which General Electric has been trading lately.

Of course, sum-of-the-parts valuations are more art than science, but other estimates also imply meaningful upside. Obin values the shares at $105, and Melius Research analyst Scott Davis, at $118.

Whatever the final value turns out to be, the breakup of GE is what its businesses need to enjoy a rebirth. If he were still around, Thomas Edison might not like it, but investors in the humbled giant should be pleased.

WSJ : Pfizer in Advanced Talks to Buy Global Blood Therapeutics for About $5 Bil

Pfizer in Advanced Talks to Buy Global Blood Therapeutics for About $5 Billion
A deal would be the latest move by the drug giant to bolster its portfolio and pipeline

Pfizer Inc. PFE -1.18% is in advanced talks to buy Global Blood Therapeutics Inc., GBT 33.03% the maker of a recently approved drug for sickle-cell disease, for about $5 billion, in the latest move by the drug giant to bolster its portfolio and pipeline.

Pfizer is aiming to seal a deal for GBT in the coming days, according to people familiar with the matter. The situation is still fluid, and other suitors are still in the mix, some of the people said. GBT announces its second-quarter results Monday.

Bloomberg reported earlier this week that potential buyers were circling GBT, without naming them. The shares shot up on the news, adding to earlier gains since the spring. They closed Friday up 33% at $63.84 after The Wall Street Journal reported on the talks with Pfizer, giving GBT a market value of more than $4 billion.

GBT, of South San Francisco, was founded in 2011. Buying the company would add to Pfizer’s presence in rare diseases, furnishing a drug already on sale for the treatment of sickle-cell disease as well as two in development that have produced positive results in preliminary studies.

The commercial treatment, called Oxbryta and approved in December for children 4 to 11 years old after being cleared in 2019 for people 12 and older, had just over $55 million in first-quarter sales.

Sickle-cell disease is an inherited blood disorder affecting about 100,000 people in the U.S., including 1 in 13 who are Black. Pfizer has been interested in sickle cell, but a drug it had been developing failed in 2019. It has another one in early-stage development.

There had been few drugs treating the disease, but it has drawn the interest of researchers in recent years due to scientific advances in understanding its molecular roots. Treatments like Oxbryta could face competition from gene therapies in development.

Pfizer has been looking to add products to its lineup and pipeline, as the company seeks to find long-running sales growth that doesn’t depend on pandemic products.

Pfizer’s Covid-19 vaccine and pill have driven huge revenue. The company projects $54 billion in sales from the two products this year alone. Yet analysts expect demand to drop in coming years, putting pressure on the company’s non-pandemic portfolio.

The New York-based drugmaker plans to add $25 billion in revenue from business-development moves like M&A by 2030.

Flush with the cash its pandemic products have generated, Pfizer has been inking deals to bolster its portfolio and pipeline. In May, it agreed to buy the rest of migraine drugmaker Biohaven Pharmaceutical Holding Co. for $11.6 billion.

Earlier, Pfizer had bought Arena Pharmaceuticals for $6.7 billion and said it would acquire privately held respiratory virus drugmaker Reviral Ltd.

If the deal for GBT comes together, it would add to a flurry of recent healthcare tie-ups. This week, Gilead Sciences Inc. agreed to buy the privately held U.K. biotech MiroBio for around $400 million and Amgen Inc. agreed to buy California-based ChemoCentryx Inc. for roughly $4 billion. Meanwhile, Merck & Co. has been eyeing a deal for Seagen Inc. that would be valued at around $40 billion and broaden its lineup of cancer drugs. Still, healthcare deal volumes are down by nearly 50% compared with this time last year, according to Dealogic data.

>>> Europe : Brokers Upgrades & Downgrades - 5th of august 2022

>>> Up
* Chevron Raised to Buy at SocGen
* Covestro Raised to Buy at Jefferies; PT 40 euros
* Eli Lilly PT Raised to $360 from $335 at Cantor
* Glaston Raised to Buy at Inderes; PT 1.20 euros
* JDE Peet's Raised to Hold at Jefferies; PT 31 euros
* Kellogg Raised to Neutral at Piper Sandler; PT $74
* Lehto Group Raised to Reduce at Inderes; PT 35 euro cents
* Nurminen Logistics Raised to Accumulate at Inderes; PT 1 euro

>>> Down
* Assa Abloy Cut to Hold at Jefferies; PT 250 kronor
* BASF Cut to Hold at Jefferies; PT 47 euros
* Beiersdorf Cut to Hold at Deutsche Bank; PT 105 euros
* CapMan Cut to Accumulate at Inderes; PT 3.30 euros
* ConvaTec Cut to Neutral at BofA
* Hikma Cut to Equal-Weight at Barclays; PT 1,750 pence
* Just Eat Takeaway Cut to Sell at Numis; PT 15 euros
* Lanxess Cut to Neutral at Citi; PT 40 euros
* Legrand Cut to Hold at Jefferies; PT 79 euros
* Mediclinic Cut to Hold at Jefferies; PT 501 pence
* Next Cut to Neutral at Goldman; PT 7,600 pence
* Shop Apotheke Cut to Hold at Berenberg; PT 110 euros

>>> Initiation
* Marel HF Rated New Hold at Jefferies

>>> Call
* *BOFA STRATEGISTS CUT EUROPEAN STOCKS TO NEGATIVE FROM NEUTRAL
* Assa Abloy Cut at Jefferies as End Markets Start to Normalize
* Covestro Raised, BASF Cut as Jefferies Tweaks Chemicals Ratings
* JDE Peet’s Confounds Skepticism, Upgraded to Hold at Jefferies
* Lanxess Resumed Neutral at Citi on Cautious Near-Term Macro View
* Legrand Downgraded to Hold at Jefferies on Risks to US Growth
* Shop Apotheke Cut at Berenberg on Exected E-Prescription Delays

>>> What to look at today - 5th of August 2022

Stocks in Asia climbed along with US equity futures on Friday, helped by gains in technology shares, and oil snapped a slide as investor sentiment steadied after another turbulent week. An Asian equity index rose 0.8%, while S&P 500, Nasdaq 100 and European contracts posted modest gains. Taiwan recouped losses fueled by US House Speaker Nancy Pelosi’s visit, a jump that may have helped the wider mood. The 10-year Treasury yield was steady at about 2.68% and the dollar edged up. The inversion between two-year and 10-year yields remained near the deepest since 2000, indicating worries about a recession as monetary policy tightens.  A global equity index is set for a third weekly advance and near a two-month peak in a recovery from bear-market lows, helped by resilient US company profits. The durability of the bounce remains in doubt as borrowing costs go up. Democrats agreed on a revised version of their tax and climate bill, adding a new 1% excise tax on stock buybacks. Investors are also monitoring the aftermath of Pelosi’s visit to Taiwan. China, which regards the self-ruled island as part of its territory, reportedly fired missiles over Taiwan during military drills -- a major escalation if confirmed. US After Hours Summary: Very busy earnings session; headliners: FUBO +25.4%, NET +21.2%, CVNA +14.7%, YELP +14.6%, DASH +13.7%, TEAM +10.2%, LYFT +9.1% on upside; DOCS -16.5%, CDNA -13.3%, MNTV -11.8%, WBD -11.4% on downside

Nikkei +0,86% Hang Seng -0,06% CSI +0,29% Shanghai +0,26% Shenzen +0,39%

Eur$ 1,0230 CNH 6,7509 CNY 6,7465 JPY 133,40 GBP 1,2139 CHF 0,9568 RUB 61,1261 TRY 17,9445 WTI$ 88,94 +0,50% Gold 1,791,04 -1,10% BTC 23,100 +3,2% ETH 1,653 +4%

S&P +0,23% Nasdaq +0,26% EuroStoxx +0,16% FTSE +0,15% Dax +0,18% SMI +0,16%

Macro :
- US Buyback Tax Could Be Friday’s S&P 500 Tail Risk
- Crypto Lender Voyager Receives Multiple Bids Above FTX Offer
- *BOFA STRATEGISTS CUT EUROPEAN STOCKS TO NEGATIVE FROM NEUTRAL

Keep an eye on :
- AED BB : Aedifica 1H EPRA EPS Beats Estimates
- AD NA : Ahold Delhaize to Postpone Amsterdam IPO of Bol.com
- AKTIA FH : Aktia Bank 2Q Adjusted EPS Misses Estimates
- ATUS US : Altice USA Eyes PE Infrastructure Funds for Suddenlink Sale:CNBC
- ALV GY : Allianz 2Q Operating Profit Beats Estimates
- ALV GY : Pimco Clients Pull Out $29 Billion as Allianz Sees Profit Rise
- AAL LN : Anglo Studies Chile Project Rejection With View to Seek Review
- AMGN US : Amgen 2Q Adjusted EPS Beats Estimates: Snapshot
- ATL IM : Atlantia FY Revenue Forecast Beats Estimates
- ATL IM : Atlantia Approves Mutually Agreed Exit of CEO Bertazzo
- ATCO US : Atlas Chairman, Fairfax Consortium Jointly Proposes to Buy Atlas
- NDA GY : Aurubis 9M Pretax Operating Profit EU448M Vs. EU268M Y/y
- BAVA DC : Monkeypox Declared a US Health Emergency, Freeing Up Funding
- BYND US : Beyond Meat Cuts Sales Forecast as Shoppers Trade Down
- BITTI FH : Bittium 2Q Operating Profit Beats Estimates
- BPE IM : BPER Banca 2Q Revenue EU903.2M Vs. EU840.7M Y/y
- BPOST BB : Bpost 2Q IFRS Net Beats Estimates
- BMW GY : European Lithium, BMW in Non-binding MOU on Lithium Hydroxide
- AFX GY : Carl Zeiss Meditec Sees FY Revenue at Least EU1.8B
- COR PL : Corticeira Amorim Buys Plot of Land From Novo Banco for EU22.3m
- CE IM : Credito Emiliano 2Q Net Income Beats Estimates
- DPW GY : Deutsche Post 2Q Ebit Beats Estimates
- DASH US : DoorDash Soars 11% After Results and Ebitda Forecast
- DBX US : Dropbox 2Q Adjusted EPS Beats Estimates
- EDF FP : EDF May Be Evaluating Sale of Italy’s Edison, MF Reports
- EXPE US : Expedia 2Q Adjusted EPS Beats Estimates
- GLPG NA : Galapagos Boosts FY Operating Cash Burn Forecast
- ILTY IM : Illimity 2Q Operating Income EU80.6M
- IPI US : Intrepid Potash 2Q Adjusted EPS Misses Estimates
- INGA NA : *ING GROUP FILES $20B MIXED-SECURITIES SHELF
- INW IM : Infrastrutture Wireless CEO Resigns as Sale of Shares Closes
- IPN FP : Ipsen Extends Expiration Date of Offer for Epizyme to Aug. 11
- ITA IM : ITA Airways Sale Won’t Be Left to Next Government: Draghi
- KKR US : KKR to Team Up With Loop Capital to Offer Equity Research, Firm Officials Say -- WSJ
- LGF/A US : Lions Gate Buyers Are Interested in Its Film Studio and Starz
- LSE LN :
- LHA GY : Lufthansa Seals Ground Crew Wage Deal to Avert Further Walkouts
- META US : Meta Makes Bond-Market Debut With $10 Billion Jumbo Deal
- MOBN SW : Mobimo 1H Ebit CHF81.4M Vs. CHF115.4M Y/y
- BMPS IM : Monte Paschi 2Q Net Income EU17.5M Vs. EU82.8M Y/y
- MNST US : Monster Beverage Shares Fall After 2Q Margins, EPS Miss
- NTGY SM :
- ORRON SS : Orron Eyes Possible Expansion Into Europe as Energy Demand Rises
- PIRC IM : Pirelli FY Revenue Forecast Beats Estimates; Raises FY Guidance
- RHM GY : Rheinmetall 1H Operating Profit EU206M Vs. EU191M Y/y
- ROTH FP : Rothschild & Co 1H EPS EU3.43 Vs. EU4.78 Y/y
- SAN FP : Innovent, Sanofi to Develop Cancer Medicines in China
- TWTR US : Musk Says Twitter Played ‘Hide-and-Seek’ as He Sought Info
- TWTR US : *TWITTER SAYS MUSK ACCUSING IT OF FRAUD IN MERGER COUNTERSUIT
- UBI FP : Ubisoft Surges on Possible Tencent Bigger Stake: Street Wrap
- UNI IM : Unipol 1H Consolidated Net EU574.9M Vs. EU536.7M Y/y
- US IM : UnipolSai 1H Consolidated Net EU401.5M Vs. EU525.8M Y/y
- VOW GY : Porsche Is Said to Court Gulf Sovereign Funds for Landmark IPO
- WPP LN : *WPP RAISES FY COMP SALES GUIDANCE ON `STRONG' 1H PERFORMANCE
- XIOR BB : Xior 1H Net Rental Income EU49.8M Vs. EU35.2M Y/y
- XPO US : XPO Logistics Boosts FY Adjusted EPS Forecast, Beats Estimates
- XPO US : XPO Logistics CEO Jacobs to Step Aside After Brokerage Spinoff
- YELP US : Yelp Boosts FY Adjusted Ebitda Forecast, Beats Estimates
- ZAL GY : Zalando Changes Track With Focus on Profitability: Handelsblatt